Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

N-(4-Hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells

Oncogene volume 25, pages 2785–2794 (2006)Cite this article

Abstract

N-(4-hydroxyphenyl)retinamide (4HPR), a synthetic retinoid effective in cancer chemoprevention and therapy, is thought to act via apoptosis induction resulting from increased reactive oxygen species (ROS) generation. As ROS can activate MAP kinases and protein kinase C (PKC), we examined the role of such enzymes in 4HPR-induced apoptosis in HNSCC UMSCC22B cells. 4HPR increased ROS level within 1 h and induced activation of caspase 3 and PARP cleavage within 24 h. Activation of MKK3/6 and MKK4, JNK, p38 and ERK was detected between 6 and 12 h, increased up to 24 h and preceded apoptosis. 4HPR-induced activation of these kinases was abrogated by the antioxidants BHA and vitamin C. SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis. Suppression of JNK1 and JNK2 using siRNA decreased, whereas overexpression of wild type-JNK1 enhanced 4HPR-induced apoptosis. PD169316, a p38, inhibitor suppressed phosphorylation of Hsp27 and apoptosis. PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR. Likewise, PKC inhibitor GF109203X suppressed ERK and p38 phosphorylation and PARP cleavage. These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M et al. (1997). J Clin Invest 100: 1813–1821.

  • Asumendi A, Morales MC, Alvarez A, Arechaga J, Perez-Yarza G . (2002). Br J Cancer 86: 1951–1956.

  • Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). Proc Natl Acad Sci USA 98: 13681–13686.

  • Bhatt NY, Kelley TW, Khramtsov VV, Wang Y, Lam GK, Clanton TL et al. (2002). J Immunol 169: 6427–6434.

  • Boya P, Morales MC, Gonzalez-Polo RA, Andreau K, Gourdier I, Perfettini JL et al. (2003). Oncogene 22: 6220–6230.

  • Carvalho H, Evelson P, Sigaud S, Gonzalez-Flecha B . (2004). J Cell Biochem 92: 502–513.

  • Chang L, Karin M . (2001). Nature 410: 37–40.

  • Chen YR, Tan TH . (2000). Int J Oncol 16: 651–662.

  • Chen YR, Zhou G, Tan TH . (1999). Mol Pharmacol 56: 1271–1279.

  • Davis RJ . (2000). Cell 103: 239–252.

  • Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA . (1997). Carcinogenesis 18: 943–948.

  • Donovan N, Becker EB, Konishi Y, Bonni A . (2002). J Biol Chem 277: 40944–40949.

  • Formelli F, Barua AB, Olson JA . (1996). FASEB J 10: 1014–1024.

  • Freemantle SJ, Spinella MJ, Dmitrovsky E . (2003). Oncogene 22: 7305–7315.

  • Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR et al. (2003). Clin Cancer Res 9: 2032–2039.

  • Guise S, Braguer D, Carles G, Delacourte A, Briand C . (2001). J Neurosci Res 63: 257–267.

  • Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ . (1996). J Biol Chem 271: 4138–4142.

  • Hail Jr N, Lotan R . (2000). Cancer Epidemiol Biomarkers Prev 9: 1293–1301.

  • Hail Jr N, Lotan R . (2001). J Biol Chem 276: 45614–45621.

  • Ichijo H . (1999). Oncogene 18: 6087–6093.

  • Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q et al. (2000). J Biol Chem 275: 322–327.

  • Kim DG, You KR, Liu MJ, Choi YK, Won YS . (2002). J Biol Chem 277: 38930–38938.

  • Kim HJ, Lotan R . (2004). Cancer Res 64: 2439–2448.

  • Kroemer G, Reed JC . (2000). Nat Med 6: 513–519.

  • Kyriakis JM, Avruch J . (2001). Physiol Rev 81: 807–869.

  • Lee YJ, Cho HN, Soh JW, Jhon GJ, Cho CK, Chung HY et al. (2003). Exp Cell Res 291: 251–266.

  • Liao YF, Hung YC, Chang WH, Tsay GJ, Hour TC, Hung HC et al. (2005). Life Sci 77: 707–719.

  • Lotan R . (1996). FASEB J 10: 1031–1039.

  • Lovat PE, Oliverio S, Ranalli M, Corazzari M, Rodolfo C, Bernassola F et al. (2002). Cancer Res 62: 5158–5167.

  • Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, Bernassola F, Piacentini M, Malcolm AJ et al. (2000). Exp Cell Res 260: 50–60.

  • Luo Y, Umegaki H, Wang X, Abe R, Roth GS . (1998). J Biol Chem 273: 3756–3764.

  • Malone W, Perloff M, Crowell J, Sigman C, Higley H . (2003). Expert Opin Investig Drugs 12: 1829–1842.

  • Martindale JL, Holbrook NJ . (2002). J Cell Physiol 192: 1–15.

  • Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP . (1999). J Natl Cancer Inst 91: 1138–1146.

  • McLaughlin MM, Kumar S, McDonnell PC, Van Horn S, Lee JC, Livi GP et al. (1996). J Biol Chem 271: 8488–8492.

  • Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H . (2004). Carcinogenesis 25: 647–659.

  • Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T, Sugimoto T . (2004). Int J Cancer 112: 219–224.

  • Poot M, Hosier S, Swisshelm K . (2002). Exp Cell Res 279: 128–140.

  • Reed JC . (1999). J Natl Cancer Inst 91: 1099–10100.

  • Reynolds CP . (2004). Pediatr Transplant 8 (Suppl 5): 56–66.

  • Robertson JD, Orrenius S . (2002). Toxicology 181–182: 491–496.

  • Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D et al. (1994). Cell 78: 1027–1037.

  • Schonwasser DC, Marais RM, Marshall CJ, Parker PJ . (1998). Mol Cell Biol 18: 790–798.

  • Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M . (2001). Exp Cell Res 268: 84–92.

  • Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N . (2003). Mol Carcinogen 36: 115–122.

  • Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N . (2002). Mol Carcinogen 35: 127–137.

  • Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G et al. (2000). J Biol Chem 275: 12200–12206.

  • Sun SY, Hail Jr N, Lotan R . (2004). J Natl Cancer Inst 96: 662–672.

  • Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R . (1999). Cancer Res 59: 2493–2498.

  • Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R . (1999). Oncogene 18: 6380–6387.

  • Tamura Y, Simizu S, Osada H . (2004). FEBS Lett 569: 249–255.

  • Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K et al. (2001). EMBO Rep 2: 222–228.

  • Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. (2000). Science 288: 870–874.

  • Traore K, Trush MA, George Jr M, Spannhake EW, Anderson W, Asseffa A . (2005). Leuk Res 29: 863–879.

  • Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y et al. (2004). EMBO J 23: 1889–1899.

  • Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S . (1996). J Biol Chem 271: 23512–23519.

  • Ulukaya E, Pirianov G, Kurt MA, Wood EJ, Mehmet H . (2003). Cell Death Differ 10: 856–859.

  • Wang X, Martindale JL, Holbrook NJ . (2000). J Biol Chem 275: 39435–39443.

  • Won YK, Ong CN, Shen HM . (2005). Carcinogenesis 26: 2149–2156.

  • Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME . (1995). Science 270: 1326–1331.

  • Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL et al. (2004). Oncogene 23: 5594–5606.

  • Xiao D, Singh SV . (2002). Cancer Res 62: 3615–3619.

  • Yamamoto K, Ichijo H, Korsmeyer SJ . (1999). Mol Cell Biol 19: 8469–8478.

  • Yu C, Rahmani M, Dent P, Grant S . (2004). Exp Cell Res 295: 555–566.

  • Yu W, Sanders BG, Kline K . (2003). Cancer Res 63: 2483–2491.

  • Zamzami N, Kroemer G . (2003). Curr Biol 13: R71–R73.

  • Zhang X, Shan P, Sasidhar M, Chupp GL, Flavell RA, Choi AM et al. (2003). Am J Respir Cell Mol Biol 28: 305–315.

Download references

Acknowledgements

This work was supported in part by Head and Neck Cancer SPORE grant P50 CA97007 and Cancer Center Core Grant P30 CA16672-30 from the NCI.

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    H-J Kim, N Chakravarti, N Oridate, C Choe & R Lotan

  2. Department of Molecular Therapeutics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    F-X Claret

Authors
  1. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Chakravarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Oridate
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Choe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F-X Claret
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Lotan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Lotan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HJ., Chakravarti, N., Oridate, N. et al. N-(4-Hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25, 2785–2794 (2006). https://doi.org/10.1038/sj.onc.1209303

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209303

Keywords

This article is cited by

Search

Advanced search

Quick links